Jean-Francois Korobelnik, MD, professor of ophthalmology, University Hospital of Bordeaux, explained findings of an analysis of the Phase 3 PULSAR trial designed to assess disease activity control. Dr Korobelink also notes how these results can be interpreted for clinicians.
Age-related macular degeneration (AMD) is the leading cause of vision loss in older Americans, affecting the central part of the retina called the macula. Alla Goldberg, MD, a…
Kenneth C. Fan, MD, MBA, Retinal Consultants of Texas, discusses how increased doses of aflibercept can be used to treat patients with wet age-related macular degeneration and diabetic…
Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes. It occurs when long-term high blood sugar damages retinal blood vessels, causing them…
Imran Ahmad, MD, outlines the diagnosis and management of diabetic macular edema, emphasizing screening gaps, socioeconomic barriers, and treatment options in developing countries. He reviews evidence-based protocols, the…
Mark R. Barakat, MD, founder and director of research, Retina Macula Institute of Arizona, discusses an analysis of the Phase 2/3 PHOTON trial. Dr Barakat explained that pre-dose…
Andrew Chang, MBBS, PhD, consultant ophthalmologist and head of Ophthalmology, Sydney Eye Hospital, Australia, shares real-world experience using 8-mg intravitreal aflibercept for neovascular age-related macular degeneration and reports…
Wet age-related macular degeneration (AMD) is a chronic, progressive eye disease marked by abnormal blood vessel growth beneath the retina. These fragile vessels can leak fluid or blood…
Anti-VEGF injections are a common treatment for wet age-related macular degeneration (AMD), aimed at preserving or even improving vision by stopping abnormal blood vessel growth under the macula.…
Richard Gale, MBChB, PhD, professor of ophthalmology, Hull York Medical School, UK, presents long-term real-world outcomes of intravitreal aflibercept 8 mg in patients with diabetic macular edema. Over…
Charles C. Wykoff, MD, highlights both the success and the limitations of current treatments for wet AMD. While anti-VEGF therapies are effective at controlling bleeding and leakage in…
